- Home
- LGVN vs BGLC Comparison
LGVN vs BGLC Comparison
Compare LGVN & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- BGLC
- Stock Information
- Founded
- LGVN 2014
- BGLC 2017
- Country
- LGVN United States
- BGLC Malaysia
- Employees
- LGVN N/A
- BGLC N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- BGLC Medical Specialities
- Sector
- LGVN Health Care
- BGLC Health Care
- Exchange
- LGVN Nasdaq
- BGLC Nasdaq
- Market Cap
- LGVN 30.0M
- BGLC 7.6M
- IPO Year
- LGVN 2021
- BGLC N/A
- Fundamental
- Price
- LGVN $2.05
- BGLC $0.38
- Analyst Decision
- LGVN Strong Buy
- BGLC
- Analyst Count
- LGVN 2
- BGLC 0
- Target Price
- LGVN $8.00
- BGLC N/A
- AVG Volume (30 Days)
- LGVN 393.9K
- BGLC 116.1K
- Earning Date
- LGVN 11-08-2024
- BGLC 11-20-2024
- Dividend Yield
- LGVN N/A
- BGLC N/A
- EPS Growth
- LGVN N/A
- BGLC N/A
- EPS
- LGVN N/A
- BGLC N/A
- Revenue
- LGVN $1,229,000.00
- BGLC $9,183,168.00
- Revenue This Year
- LGVN $161.78
- BGLC N/A
- Revenue Next Year
- LGVN $8.62
- BGLC N/A
- P/E Ratio
- LGVN N/A
- BGLC N/A
- Revenue Growth
- LGVN 39.34
- BGLC N/A
- 52 Week Low
- LGVN $0.77
- BGLC $0.31
- 52 Week High
- LGVN $23.90
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- LGVN 52.20
- BGLC 41.00
- Support Level
- LGVN $1.76
- BGLC $0.38
- Resistance Level
- LGVN $2.26
- BGLC $0.49
- Average True Range (ATR)
- LGVN 0.12
- BGLC 0.02
- MACD
- LGVN 0.05
- BGLC -0.00
- Stochastic Oscillator
- LGVN 58.00
- BGLC 32.66
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.